Global Cancer Generics Market Forecast to 2022

Description: Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.

As per the report “Global Cancer Generics Market Forecast to 2022”, the global cancer generics market is anticipated to witness a double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global cancer generics market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global cancer generics market.

The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.

Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.

Based on geography, the report divides market into North America, Europe, and Asia-Pacific. In 2016, North America is estimated to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global generics industry.

The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.

Contents:

1. Analyst View
2. Research Methodology
3. Global Cancer Drugs Market Outlook 2022
   3.1 Cancer Incidences
   3.2 Cancer Drug Market
4. Market Drivers & Challenges
   4.1 Drivers
      4.1.1 Increasing Cancer Incidences
      4.1.2 Strategic Collaborations
      4.1.3 Growing Geriatric Population
      4.1.4 Ability to Curb Healthcare Cost
   4.2 Challenges
      4.2.1 Growing Backlog of Generic Drug Applications
      4.2.2 Counterfeit Generic Drugs
   4.3 Opportunities
      4.3.1 Patent Expiry of Blockbuster Oncology Drugs
      4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries
5. Global Cancer Generics Market Analysis 2022
6. Global Cancer Generics Market by Mode of Administration
6.1 Oral Generics
   6.1.1 Arimidex (Anastrozole)
   6.1.2 Femara (Letrozole)
   6.1.3 Hycamtin (Topotecan)
   6.1.4 Stivarga (Regorafenib)
   6.1.5 Tarceva (Erlotinib)
   6.1.6 Xalkori (Crizotinib)
   6.1.7 Xeloda (Capecitabine)
   6.1.8 Gleevec/Glivec (Imatinib Mesylate)
   6.1.9 Nolvadex (Tamoxifen Citrate)
   6.1.10 Targretin (Bexarotene)

6.2 Injectables Generics
   6.2.1 Camptosar (Irinotecan Hydrochloride)
   6.2.2 Eloxatin (Oxaliplatin)
   6.2.3 Gemzar (Gemcitabine Hydrochloride)
   6.2.4 Navelbine (Vinorelbine Tartrate)
   6.2.5 Platinol (Cisplatin)
   6.2.6 Taxol (Paclitaxel)
   6.2.7 Taxotere (Docetaxel)
   6.2.8 Fusilev (Levoleucovorin)
   6.2.9 Ellence (Epirubicin Hydrochloride)
   6.2.10 Adriamycin (Doxorubicin Hydrochloride)

7. Global Cancer Generics Market by Major Indications
   7.1 Lung Cancer
   7.2 Breast Cancer
   7.3 Colorectal Cancer
   7.4 Stomach Cancer
   7.5 Prostate Cancer

8. Global Cancer Generics Market by Geographic Regions
   8.1 US
   8.2 Europe
   8.3 Asia-Pacific

9. Trends & Developments
   9.1 Generic Version of Blockbuster Cancer Drug
   9.2 Entry of Indian Generic Cancer Drug in US

10. Mergers & Acquisitions

11. Key Players
   11.1 Fresenius Kabi AG
   11.2 Pfizer Inc
   11.3 Teva Pharmaceutical Industries Ltd
   11.4 Mylan N.V
   11.5 Sun Pharmaceutical Industries Ltd
   11.6 Sandoz International GmbH - A Novartis Company
   11.7 Sanofi
   11.8 Dr. Reddy's Laboratories Ltd
   11.9 Cipla Ltd
   11.10 Apotex Inc

List of Figures:

Figure 3-1: Global - Cancer Incidences (Million), 2015 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2015
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2016 & 2022
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 6-1: Global - Cancer Generics Market by Mode of Administration (%), 2016
Figure 7-1: Global - Cancer Generics Market by Major Indications (%), 2016
Figure 7-2: Global - Lung Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-3: Global - Lung Cancer Incidences (Million), 2015 & 2025
Figure 7-4: Global - Breast Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-5: Global - Breast Cancer Incidences (Million), 2015 & 2025
Figure 7-6: Global - Colorectal Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-7: Global - Colorectal Cancer Incidences (Million), 2015 & 2025
Figure 7-8: Global - Stomach Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-9: Global - Stomach Cancer Incidences (Million), 2015 & 2025
Figure 7-10: Global - Prostate Cancer Generics Market (Billion US$), 2016 & 2022
Figure 7-11: Global - Prostate Cancer Incidences (Million), 2015 & 2025

Figure 8-1: Global - Cancer Generics Market by Geographic Regions (%), 2016
Figure 8-2: US - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-3: US - Cancer Incidences (Million), 2015 & 2025
Figure 8-4: Europe - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-5: Europe - Cancer Incidences (Million), 2015 & 2025
Figure 8-6: Asia-Pacific - Cancer Generics Market (Billion US$), 2016 & 2022
Figure 8-7: Asia-Pacific - Cancer Incidences (Million), 2015 & 2025

Figure 11-1: Fresenius Kabi AG - Sales by Product Segment (%), 2015
Figure 11-2: Fresenius Kabi AG - Sales by Geographic Region (%), 2015
Figure 11-3: Pfizer Inc - Revenue by Business Segment (%), 2015
Figure 11-4: Pfizer Inc - Revenue by Geographic Region (%), 2015
Figure 11-5: Teva Pharmaceutical - Revenue by Business Segment (%), 2015
Figure 11-6: Teva Pharmaceutical - Revenue by Geographic Region (%), 2015
Figure 11-7: Mylan N.V. - Revenue by Business Segment (%), 2015
Figure 11-8: Mylan N.V. - Revenue by Geographic Region (%), 2015
Figure 11-9: Sun Pharmaceutical - Total Income by Business Segment (%), FY 2016
Figure 11-10: Sun Pharmaceutical - Total Income by Geographic Region (%), FY 2016
Figure 11-11: Sandoz International GmbH - Net Sales by Franchise (%), 2015
Figure 11-12: Sanofi - Sales by Business Segment (%), 2015
Figure 11-13: Sanofi - Sales by Geographic Region (%), 2015
Figure 11-14: Dr. Reddy’s Laboratories - Revenue by Business Segment (%), FY 2016
Figure 11-15: Dr. Reddy’s Laboratories - Revenue by Geographic Region (%), FY 2016
Figure 11-16: Cipla Ltd. - Revenue by Geographic Region (%), FY 2016

List of Tables:
Table 3-1: Most Prevalent Types of Cancer, 2015
Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 6-1: List of Companies Dealing in Generic Arimidex
Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 6-3: List of Companies Dealing in Generic Femara
Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 6-5: List of Companies Dealing in Generic Hycamtin
Table 6-6: List of Companies Dealing in Generic Xeloda
Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 6-8: List of Companies Dealing in Generic Gleevec
Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate)
Table 6-10: List of Companies Dealing in Generic Nolvadex
Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
Table 6-12: List of Companies Dealing in Generic Targetin
Table 6-13: List of Companies Dealing in Generic Camptosar
Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 6-16: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 6-17: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 6-18: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 6-19: List of Companies Dealing in Generic Platolin (Cisplatin)
Table 6-20: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 6-21: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 6-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 6-23: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-24: List of Companies Dealing in Generic Fusilev (Levoleucovorin)
| Table 6-25: List of Companies Dealing in Generic Ellence (Epirubicin Hydrochloride) |
| Table 6-26: List of Companies Dealing in Generic Adriamycin (Doxorubicin Hydrochloride) |
| Table 7-1: Global - Key Lung Cancer Drugs and Patent Expiry Status |
| Table 7-2: Global - Key Breast Cancer Drugs and Patent Expiry Status |
| Table 7-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status |
| Table 7-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status |
| Table 7-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status |
| Table 10-1: Global - Major M&A in the Generics Industry (2014-2016) |
| Table 11-1: Fresenius Kabi AG - Sales (Billion US$), 2013, 2014 & 2015 |
| Table 11-2: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs |
| Table 11-3: Pfizer Inc - Revenue (Billion US$), 2013, 2014 & 2015 |
| Table 11-4: Pfizer Inc - Key Cancer Generic Products |
| Table 11-5: Teva Pharmaceutical - Revenue (Billion US$), 2013, 2014 & 2015 |
| Table 11-6: Teva Pharmaceutical - Key Cancer Generic Drugs |
| Table 11-7: Mylan N.V. - Revenue (Billion US$), 2013, 2014 & 2015 |
| Table 11-8: Mylan N.V. - Key Cancer Generic Drugs |
| Table 11-9: Sun Pharmaceutical - Total Income (Billion US$), FY 2014, FY 2015 & FY 2016 |
| Table 11-10: Sun Pharmaceutical - Key Cancer Generic Drugs |
| Table 11-11: Sandoz International GmbH - Sales (Billion US$), 2013, 2014 & 2015 |
| Table 11-12: Sandoz International GmbH - Key Cancer Generic Drugs |
| Table 11-13: Sanofi - Net Sales (Billion US$), 2013, 2014 & 2015 |
| Table 11-14: Sanofi - Key Cancer Generic Drugs |
| Table 11-15: Dr. Reddy's Laboratories - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016 |
| Table 11-16: Dr. Reddy's Laboratories - Key Cancer Generic Drugs |
| Table 11-17: Cipla Ltd. - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016 |
| Table 11-18: Cipla Ltd. - Key Cancer Generic Drugs |
| Table 11-19: Apotex Inc. - Key Cancer Generic Drugs |

Ordering:  
Order Online - [http://www.researchandmarkets.com/reports/3926615/](http://www.researchandmarkets.com/reports/3926615/)  
Order by Fax - using the form below  
Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Cancer Generics Market Forecast to 2022
Web Address: http://www.researchandmarkets.com/reports/3926615/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1400</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 1600 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 1600 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 2000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: __________________________________________ Last Name: _______________________________________
Email Address: * ______________________________________
Job Title: __________________________________________
Organisation: _______________________________________
Address: __________________________________________
City: ______________________________________________
Postal / Zip Code: __________________________________
Country: __________________________________________
Phone Number: ______________________________________
Fax Number: ________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp